Long-lasting remission induced by rituximab in two cases of refractory autoimmune haemolytic anaemia due to cold agglutinins

Blood Transfusion

Volumn 7, Issue 3, 2009, Pages 235-236

  Palombi, Massimiliano ^a   Niscola, Pasquale ^a   Trawinska, Malgorzata Monika ^a   Scaramucci, Laura ^a   Giovannini, Marco ^a   Perrotti, Alessio ^a   De Fabritiis, Paolo ^a  

^a S EUGENIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLD AGGLUTININ; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEMOGLOBIN; PREDNISONE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MALE; PHYSICAL EXAMINATION; REMISSION; TREATMENT OUTCOME;

ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS;

EID: 67749099833     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0066-08     Document Type: Letter

References (5)

1. Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev 2008;22:1-15.
2. Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol 2002;68:243-246
3. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103:2925-2928
4. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006; 47:253-260
5. Panwar U, Mathews C, Cullis JO. Cost-effectiveness of rituximab in refractory cold agglutinin disease. Int J Lab Hematol 2008; 30:331-333